EA201791067A1 - Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса - Google Patents

Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса

Info

Publication number
EA201791067A1
EA201791067A1 EA201791067A EA201791067A EA201791067A1 EA 201791067 A1 EA201791067 A1 EA 201791067A1 EA 201791067 A EA201791067 A EA 201791067A EA 201791067 A EA201791067 A EA 201791067A EA 201791067 A1 EA201791067 A1 EA 201791067A1
Authority
EA
Eurasian Patent Office
Prior art keywords
syndrome
methods
channels
prader
smith
Prior art date
Application number
EA201791067A
Other languages
English (en)
Other versions
EA036103B1 (ru
Inventor
Нейл М. Коуэн
Original Assignee
Эссэнтиалис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эссэнтиалис, Инк. filed Critical Эссэнтиалис, Инк.
Publication of EA201791067A1 publication Critical patent/EA201791067A1/ru
Publication of EA036103B1 publication Critical patent/EA036103B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Steroid Compounds (AREA)

Abstract

В настоящем изобретении предлагается однократное или длительное введение субъекту фармацевтических составов веществ, открывающих Kканалы, в некоторых случаях в комбинации с гормоном роста, для достижения ранее не известных фармакодинамических, фармакокинетических, терапевтических, физиологических и метаболических результатов при лечении заболеваний или патологических состояний, в патогенез которых вовлечены Kканалы. Также предлагаются фармацевтические составы, способы введения и дозы веществ, открывающих Kканалы, посредством чего у индивидуумов, получающих лечение, достигают указанных результатов при одновременном снижении частоты нежелательных эффектов. Кроме того, предлагаются способы совместного введения веществ, открывающих Kканалы, с другими лекарственными средствами (например, в комбинации с гормоном роста) для лечения заболеваний у людей и животных (например, при синдроме Прадера-Вилли, синдроме Смита-Магениса и подобных.
EA201791067A 2014-11-14 2015-11-12 Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса EA036103B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462080150P 2014-11-14 2014-11-14
US201562138245P 2015-03-25 2015-03-25
US201562170035P 2015-06-02 2015-06-02
US201562221359P 2015-09-21 2015-09-21
PCT/US2015/060455 WO2016077629A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Publications (2)

Publication Number Publication Date
EA201791067A1 true EA201791067A1 (ru) 2017-11-30
EA036103B1 EA036103B1 (ru) 2020-09-29

Family

ID=55955075

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791067A EA036103B1 (ru) 2014-11-14 2015-11-12 Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса

Country Status (20)

Country Link
US (4) US10058557B2 (ru)
EP (1) EP3217963B1 (ru)
JP (4) JP6709226B2 (ru)
KR (4) KR102323613B1 (ru)
CN (2) CN107106500B (ru)
AU (2) AU2015346196B2 (ru)
BR (1) BR112017009986A2 (ru)
CA (4) CA3125839C (ru)
DK (1) DK3217963T3 (ru)
EA (1) EA036103B1 (ru)
ES (1) ES2806977T3 (ru)
HK (1) HK1243954A1 (ru)
HU (1) HUE050895T2 (ru)
IL (1) IL252111B (ru)
MX (2) MX2017006244A (ru)
MY (1) MY187610A (ru)
NZ (1) NZ768958A (ru)
PL (1) PL3217963T3 (ru)
SG (1) SG11201703721SA (ru)
WO (1) WO2016077629A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404605B1 (en) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP2404604B1 (en) 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
AU2015346196B2 (en) 2014-11-14 2019-01-31 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
WO2017210540A1 (en) * 2016-06-03 2017-12-07 The Trustees Of Columbia University In The City Of New York Methods of treating prader-willi syndrome
EP3619222A4 (en) 2017-05-05 2021-02-17 Nino Sorgente METHODS AND COMPOSITIONS FOR IMPROVING EYE HEALTH
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2020061414A1 (en) * 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
CN111888330B (zh) * 2020-09-18 2022-08-16 常州市第四制药厂有限公司 一种二氮嗪口服混悬溶液及制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5629045A (en) 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1998010786A2 (en) 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6197765B1 (en) 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
WO2002000223A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
TW478039B (en) 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
WO2004043534A1 (en) 2002-11-12 2004-05-27 Collegium Pharmaceutical, Inc. Inertial drug delivery system
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EP1782812A1 (en) 2004-06-23 2007-05-09 Neurotec Pharma, S.L. Compounds for the treatment of inflammation of the central nervous system
EP2404605B1 (en) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
CN101043879A (zh) * 2004-08-25 2007-09-26 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP2404604B1 (en) 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
WO2009006483A1 (en) 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
US20120238554A1 (en) 2007-07-02 2012-09-20 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
TR201900438T4 (tr) * 2011-12-15 2019-02-21 Millendo Therapeutics Sas Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
JP2014074004A (ja) * 2012-10-05 2014-04-24 Shinichi Niijima 精神症状の改善剤
WO2014197753A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
AU2015346196B2 (en) 2014-11-14 2019-01-31 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Also Published As

Publication number Publication date
CA3125839A1 (en) 2016-05-19
CN113599386A (zh) 2021-11-05
JP6709226B2 (ja) 2020-06-10
WO2016077629A1 (en) 2016-05-19
AU2015346196B2 (en) 2019-01-31
KR102323613B1 (ko) 2021-11-09
KR102598666B1 (ko) 2023-11-07
SG11201703721SA (en) 2017-06-29
US10874676B2 (en) 2020-12-29
KR102517840B1 (ko) 2023-04-05
MX2017006244A (es) 2018-02-26
IL252111B (en) 2021-09-30
CA3125835C (en) 2023-01-03
CA2966907C (en) 2021-09-07
KR20170082625A (ko) 2017-07-14
EP3217963A4 (en) 2018-07-04
KR20230049760A (ko) 2023-04-13
PL3217963T3 (pl) 2020-10-19
US20210322434A1 (en) 2021-10-21
EP3217963B1 (en) 2020-05-20
IL252111A0 (en) 2017-07-31
JP7232300B2 (ja) 2023-03-02
US10058557B2 (en) 2018-08-28
DK3217963T3 (da) 2020-07-20
CA3125839C (en) 2023-10-24
CA3125835A1 (en) 2016-05-19
MX2021003982A (es) 2022-06-09
ES2806977T3 (es) 2021-02-19
US10456408B2 (en) 2019-10-29
EP3217963A1 (en) 2017-09-20
MY187610A (en) 2021-10-04
KR102452254B1 (ko) 2022-10-11
JP2017533972A (ja) 2017-11-16
NZ768958A (en) 2021-07-30
NZ731565A (en) 2021-06-25
US20190105327A1 (en) 2019-04-11
US20200147100A1 (en) 2020-05-14
KR20210134843A (ko) 2021-11-10
CN107106500B (zh) 2021-07-30
CN107106500A (zh) 2017-08-29
HK1243954A1 (zh) 2018-07-27
AU2015346196A1 (en) 2017-06-29
JP2020073566A (ja) 2020-05-14
JP2023056025A (ja) 2023-04-18
US20180021344A1 (en) 2018-01-25
KR20220124289A (ko) 2022-09-13
EA036103B1 (ru) 2020-09-29
AU2019202906B2 (en) 2020-05-21
JP6955039B2 (ja) 2021-10-27
HUE050895T2 (hu) 2021-01-28
BR112017009986A2 (pt) 2018-02-14
JP2021193148A (ja) 2021-12-23
CA2966907A1 (en) 2016-05-19
CA3210794A1 (en) 2016-05-19
AU2019202906A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
EA201791067A1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MY187047A (en) Selective pyy compounds and uses thereof
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EA201791199A1 (ru) Способ лечения болезни альцгеймера
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MD20180049A2 (ru) Фармацевтическая композиция
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
EA201790089A1 (ru) Фармацевтические средства для лечения головокружения различной этиологии